REVIEW ARTICLES
Biocompatibility aspects of new stent technology
Olivier F. Bertrand, MD*  ,1,
Rajender Sipehia, PhD ,
Rosaire Mongrain, PhD ,
Josep Rodés, MD*,
Jean-Claude Tardif, MD*,
Luc Bilodeau, MD*,
Gilles Côté, MD, FACC* and
Martial G. Bourassa, MD, FACC*
* Research Center, Montreal Heart Institute, McGill University, Montreal, Quebec, Canada
Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada
Artificial Cells and Organs Research Centre, McGill University, Montreal, Quebec, Canada
Department of Biomedical Engineering, Montreal Heart Institute, Montreal, Quebec, Canada
Manuscript received October 9, 1997;
revised manuscript received May 4, 1998,
accepted May 15, 1998.
Address for correspondence: Dr. Olivier F. Bertrand, Interventional Cardiology Laboratories, Montreal Heart Institute, Belanger East, 5000, Montreal, Quebec, Canada H1T 1C8
ofbert{at}icm.umontreal.ca
Stent implantation represents a major step forward since the introduction of coronary angioplasty. As indications continue to expand, better understanding of the early and late biocompatibility issues appears critical. Persisting challenges to the use of intracoronary stents include the prevention of early thrombus formation and late neointima development. Different metals and designs have been evaluated in animal models and subsequently in patients. Polymer coatings have been proposed to improve the biocompatibility of metallic stents or to serve as matrix for drug delivery and they are currently undergoing clinical studies. The promises of a biodegradable stent have not yet been fulfilled although encouraging results have recently been reported. Continuous low dose-rate brachytherapy combining the scaffolding effect of the stent with localized radiation therapy has witnessed the development and early clinical testing of radioactive stents. The combined efforts of basic scientists and clinicians will undoubtedly contribute to the improvement of stent biocompatibility in the future.
|
Abbreviations and Acronyms
| | PEO/PBTP | = polyethylenoxide/polybutylene terephtalate copolymer | | PLLA | = poly-l-lactic acid | | PHBV | = polyhydroxy-butyrate-valerate copolymer | | POP | = poly(organo)phosphazene |
|
This article has been cited by other articles:
|
|
|
|
 
C. N. Ionita, A. M. Paciorek, A. Dohatcu, K. R. Hoffmann, D. R. Bednarek, J. Kolega, E. I. Levy, L. N. Hopkins, S. Rudin, and J. D. Mocco
The Asymmetric Vascular Stent: Efficacy in a Rabbit Aneurysm Model
Stroke,
March 1, 2009;
40(3):
959 - 965.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Bakhshi, M.J. Edirisinghe, A. Darbyshire, Z. Ahmad, and A.M. Seifalian
Electrohydrodynamic Jetting Behaviour of Polyhedral Oligomeric Silsesquioxane Nanocomposite
J Biomater Appl,
January 1, 2009;
23(4):
293 - 309.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Salahas, A. Vrahatis, I. Karabinos, I. Antonellis, G. Ifantis, I. Gavaliatsis, P. Anthopoulos, and A. Tavernarakis
Success, Safety, and Efficacy of Implantation of Diamond-Like Carbon-Coated Stents
Angiology,
April 1, 2007;
58(2):
203 - 210.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. A. Silva, I. P. Silva, and B. Rondot
Effect of Surface Treatments on Anodic Oxide Film Growth and Electrochemical Properties of Tantalum used for Biomedical Applications
J Biomater Appl,
July 1, 2006;
21(1):
93 - 103.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Garcia-Touchard, S. E. Burke, J. L. Toner, K. Cromack, and R. S. Schwartz
Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks
Eur. Heart J.,
April 2, 2006;
27(8):
988 - 993.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Alvarez Jr and N. K. Kapur
Drug Eluting Stent Technology: A Paradigm Shift in the Treatment and Prevention of Restenosis
Journal of Pharmacy Practice,
December 1, 2005;
18(6):
461 - 478.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Gewillig, D. E. Boshoff, J. Dens, L. Mertens, and L. N. Benson
Stenting the neonatal arterial duct in duct-dependent pulmonary circulation: new techniques, better results
J. Am. Coll. Cardiol.,
January 7, 2004;
43(1):
107 - 112.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Finkelstein, D. McClean, S. Kar, K. Takizawa, K. Varghese, N. Baek, K. Park, M. C. Fishbein, R. Makkar, F. Litvack, et al.
Local Drug Delivery via a Coronary Stent With Programmable Release Pharmacokinetics
Circulation,
February 11, 2003;
107(5):
777 - 784.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. N. Babapulle and M. J. Eisenberg
Coated Stents for the Prevention of Restenosis: Part I
Circulation,
November 19, 2002;
106(21):
2734 - 2740.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Korkmaz, E. Tayfun, H. Muderrisoglu, A. Yildirir, B. Ozin, M. Ulucam, and M. Turan
Carbon Coating of Stents Has No Effect on Inflammatory Response to Primary Stent Deployment
Angiology,
September 1, 2002;
53(5):
563 - 568.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. J. Ignarro, C. Napoli, and J. Loscalzo
Nitric Oxide Donors and Cardiovascular Agents Modulating the Bioactivity of Nitric Oxide: An Overview
Circ. Res.,
January 11, 2002;
90(1):
21 - 28.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Suzuki, G. Kopia, S.-i. Hayashi, L. R. Bailey, G. Llanos, R. Wilensky, B. D. Klugherz, G. Papandreou, P. Narayan, M. B. Leon, et al.
Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model
Circulation,
September 4, 2001;
104(10):
1188 - 1193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Al Suwaidi, P. B. Berger, and D. R. Holmes Jr
Coronary Artery Stents
JAMA,
October 11, 2000;
284(14):
1828 - 1836.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
